In March 2021 (Round 4), 11.41% of primary school pupils (95% confidence intervals: 9.54% to 13.51%) and 14.45% of secondary school pupils (95% confidence intervals: 13.22% to 15.75%) had coronavirus (COVID-19) SARS-CoV-2 antibody levels above the limit of detection.
The pupil antibody test used in the COVID-19 Schools Infection Survey (SIS) is based on oral fluid collection as this is a non-invasive alternative to collecting blood but this test has a lower sensitivity (estimated at 80%); after adjusting for the sensitivity and specificity of the test it is estimated that 13.18% and 17.03% of primary school and secondary school pupils in the 14 SIS local authorities would test positive for SARS-CoV-2 antibodies.
For local authority estimates, confidence intervals are wide so should be interpreted with caution but they indicate a wide range in antibody levels around the country; in areas where community infection rates have been relatively low throughout the pandemic the percentage of pupils with antibody levels above the limit of detection is lower than areas that have had higher rates of infection.
For secondary school pupils an estimated 5.21% and 5.47% in Bournemouth and Norfolk respectively had antibody levels above the limit of detection and 24.85% and 28.42% in Manchester and Barking and Dagenham respectively had antibody levels above the limit of detection.
The antibody conversion rate (converting from negative antibody test to positive) in oral fluid was higher between rounds 1 to 2 (November to December 2020) (12.0 per 1,000 person-weeks), compared with the rate seen between rounds 2 to 4 (5.7 per 1,000 person-weeks) for all pupils combined.
There was no significant difference between antibody conversion rates, in oral fluids, of primary school pupils (5.3 per 1,000 person-weeks) and secondary school pupils (6.5 per 1,000 person-weeks) between rounds 2 and 4.
Have you been asked to take part in the study?
For more information, please visit the SIS participant guidance page.
If you have any further questions on the COVID-19 Schools Infection Survey (SIS), you can telephone IQVIA helpline on 0800 917 9679 or email email@example.com.
In the case of the coronavirus (COVID-19), antibody conversion is the incidence of antibody test results changing from negative to positive in oral fluid and will capture both symptomatic and asymptomatic infections that may have been missed between testing rounds.
To account for the different follow-up times between the rounds (on average the follow-up time between rounds 1 and 2 was three weeks and between rounds 2 and 4 was 15 weeks), the antibody conversion rate has been calculated and expressed per 1,000 person-weeks. More details on this methodology are available.
In some cases the confidence intervals around these estimates are wide because of the small number of participants whose antibody converted and caution should be taken when interpreting results. When numbers are small, weighting the data can also mean that a small number of individuals have a large effect on the antibody conversion rate.
The antibody conversion rate (converting from negative antibody test to positive) in oral fluids was higher between rounds 1 (November 2020) to 2 (December 2020) (12.0 per 1,000 person-weeks), compared with the rate seen between rounds 2 to 4 (5.7 per 1,000 person-weeks) for all pupils combined.
There was no significant difference between antibody conversion rates of primary school pupils (5.3 per 1,000 person-weeks) and secondary school pupils (6.5 per 1,000 person-weeks) between rounds 2 and 4.
More about coronavirus
COVID-19 Schools Infection Survey Round 4 pupil antibodies
Dataset | Released 11 August 2011
Initial estimates of pupils testing positive for SARS-CoV2 antibodies from the COVID-19 Schools Infection Survey across a sample of schools, within selected local authority areas in England.
The COVID-19 Schools Infection Survey analysis was produced by the Office for National Statistics (ONS) in collaboration with our research partners at the London School of Hygiene & Tropical Medicine and Public Health England.Nôl i'r tabl cynnwys
A confidence interval gives an indication of the degree of uncertainty of an estimate, showing the precision of a sample estimate. The 95% confidence intervals are calculated so that if we repeated the study many times, 95% of the time the true unknown value would lie between the lower and upper confidence limits. A wider interval indicates more uncertainty in the estimate. Overlapping confidence intervals indicate that there may not be a true difference between two estimates. For more information, see our methodology page on statistical uncertainty.
A result is said to be statistically significant if it is likely not caused by chance or the variable nature of the samples. For more information, see our methodology page on statistical uncertainty.
Antibody conversion rate
In the case of the coronavirus (COVID-19), antibody conversion is the incidence of SARS-CoV-2 antibody test results changing from negative to positive in oral fluid and will capture both symptomatic and asymptomatic infections that may have been missed between testing rounds. In this instance we are using oral fluid tests as an indicator of serum (blood) antibodies. To account for the different follow-up times between testing rounds in the COVID-19 Schools Infection Survey (SIS) an antibody conversion rate has been calculated and expressed per 1,000 person-weeks, to allow for meaningful comparisons.
An antibody conversion rate of 1.4 per 1,000 person-weeks suggests that, out of 1,000 people on average 14 changed from negative (no antibodies) to positive (antibodies against SARS-CoV-2 detected by the test) each week between the testing rounds. More details on this methodology are available. Note that after the infection, it takes some time before the antibody levels can be detected by the test. Therefore, people who have been recently infected may not yet have a detectable antibody level.
Data presented in this bulletin are from Round 4 pupil antibodies (with comparisons with Round 1 and Round 2) of the COVID-19 Schools Infection Survey (SIS). These findings are from testing for antibodies to SARS-CoV-2 only. Results from staff antibodies (based on blood tests) in Round 4 were previously published on 27 March 2021.
Results on Round 6 current coronavirus (COVID-19) infection can be found in our bulletin published on 11 August 2021.
Estimates have been weighted and are representative of the ethnicity, gender, and age for all pupils in the sampled local authorities.
Our methodology article provides further information about response rates, survey design, how we process data and how data are analysed.
The results presented in this bulletin are from antibody tests conducted in schools in England between 15 and 31 March 2021 (referred to as Round 4).
Results have also been presented from tests conducted in schools in England between 3 and 20 November 2020 (referred to as Round 1) and between 30 November and 11 December 2020 (referred to as Round 2).
Round 3 was due to take place in late January 2021. Testing within schools for this round was cancelled because of restricted attendance in schools during the national lockdown.
In Round 4 of testing, 11,033 pupils (3,762 primary and 7,271 secondary) participated in at least one current COVID-19 infection or COVID-19 antibody test. The estimated response rate for secondary school pupils, in the year groups that participation was offered to, was 14%. The estimated response rate for primary school pupils was 22%. Details of previous rounds response rates can be found in the accompanying dataset.
Further quality and methodology information on strengths, limitations, appropriate uses, and how the data were created is available in our methodology article.
Data cleaning and quality assurance is being carried out on data collected as part of the study on an ongoing basis. All estimates presented in this bulletin are provisional results. Estimates may therefore be revised in future publications.Nôl i'r tabl cynnwys
Manylion cyswllt ar gyfer y Bwletin ystadegol
Ffôn: +44 (0)208 0390326